Journals / Journal of the Turkish-German Gynecological Association / 2010 / Cilt: 11 - Sayı: 3

Endometriyal adenokanser hücre serilerinde GnRH analogları ve oktreotidin apoptozis ve hücre proliferasyonu üzerindeki etkileri

Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines

Pages
131–136
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Apoptotic index in grade I EEC cell line among ganirelix-octreotide treated cells and leuprolide-octreotide combination therapy were respectively higher than the untreated control (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines.
📊
Key Findings & Data:After trypsinization in 0.5% in calcium magnesium, free phosphate buffer solution (CMFPBS) cells were seeded on glass slides in 24-well plates containing DMEM-F12 medium and 10% fetal calf serum as culture medium.
💡
Conclusion & Impact:Results: Apoptotic index in grade I EEC cell line among ganirelix-octreotide treated cells and leuprolide-octreotide combination therapy were respectively higher than the untreated control (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines. Material and Method: Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research. Endometrium cancer cell lines obtained from three patients were used for this study. After trypsinization in 0.5% in calcium magnesium, free phosphate buffer solution (CMFPBS) cells were seeded on glass slides in 24-well plates containing DMEM-F12 medium and 10% fetal calf serum as culture medium. Cells were incubated for 24 hours at 37ºC in 5% CO2. GnRH agonist leuprolide (Lucrin 1 µmol/L), GnRH antagonist ganirelix (Orgalutran 1 µmol/L), leuprolide with octreotide (Sandostatin 10-6 mol/L), ganirelix with octreotide and no drug were added to the wells. Apoptosis and cells proliferations were evaluated after 12, 24, 48 and 72th hours of incubation. The percentage of apoptotic cells was evaluated by TdT mediated biotin-dUTP nick-end labeling (TUNEL) method; cell proliferation was assessed by bromodeoxyuridine (BrdU) incorporation. Results: Apoptotic index in grade I EEC cell line among ganirelix-octreotide treated cells and leuprolide-octreotide combination therapy were respectively higher than the untreated control (p

Özet

Amaç: Bu çalışmanın amacı endometriyal adenokanser hücre serilerinde GnRH analogları ve oktreotidin apoptozis ve hücre proliferasyonu üzerindeki etkilerini karşılaştırmaktır. Gereç ve Yöntemler: Kocaeli Üniversitesi Tıp Fakültesi Kadın hastalıkları ve Doğum bölümünde tanı almış olan endometriyal adenokanser vakaları çalışmaya alındı. Üç hastadan alınmış olan endometriyla kanser hücre serileri bu çalışmada kullanıldı. Tripinizasyon için %0.5 lik kalsiyum magnezyum, free phosphate buffer solusyonda (CMFPBS) bekletilen hücreler daha sonra DMEM-F12 mediyumu ve %10 dana fetus serumu içiren dishlere ekildi. Hücreler 37ºC in %5 CO2 de 24 saat inkübe edildiler. GnRH agonist leuprolide (Lucrin 1 μmol/L), GnRH antagonist ganirelix (Orgalutran 1 μmol/L), leuprolide ve octreotide (Sandostatin 10-6 mol/L), ganirelix ve octreotide ve ilaçsız gruplar oluşturuldu. Apoptozis ve hücre proliferasonu inkübasyondan sonraki 12, 24, 48 ve 72. saatlerde değerlendirildi. Apoptotik hücre oranı TUNEL yöntemi ile, hücre proliferasyonu ise bromodeoxyuridine (BrdU) ilavesiyle değerlendirildi. Bulgular: Grade I endometriyal kanser hücre serisindeki apoptotik index ganirelixoctreotide ve leuprolide-octreotide combination tedavileri alan gruplarda tedavisiz gruba göre anlamlı olarak daha yüksek olarak saptandı (p

🔖

Cite This Article

SOLAKOĞLU, S., ÇALIŞKAN, E., VURAL, B., ÖZTÜRK, H. B. (2022). Endometriyal adenokanser hücre serilerinde GnRH analogları ve oktreotidin apoptozis ve hücre proliferasyonu üzerindeki etkileri. Journal of the Turkish-German Gynecological Association, Cilt: 11 - Sayı: 3, 131–136. https://ajindex.com/articles/567805

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Emons G, Heyl W. Hormonal treatment of endometrial cancer. J Cancer Res Clin Oncol 2000; 126: 619-23
  2. Latta E, Chapman WB. PTEN mutations and evolving concept in endometrial neoplasia. Curr Opin Obstet Gynecol 2002; 14: 59-65
  3. Assunção Guimarães C, Linden R. Programmed cell death. Apoptosis and alternative deathsytles. Eur J Biochem 2004; 271: 1638-50
  4. Arends MJ. Apoptosis in the endometrium. Histopathology 1999; 35: 174-8 5. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Gonadotropin releasing hormone receptor in gynecologic tumors: frequent expression in adenocarsinoma histologic types. Cancer 1994; 74: 2555-61
  5. Völker P, Gründker C, Schmidt O, Schutz KD, Emons G. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: Frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone- releasing hormone analogues. Am J Obstet Gynecol 2002; 186: 171-9
  6. Jeon YT, Kim YB, Park SY, Kim JW, Park NH, Kang SB, et al. Gonadotropin- releasing hormone receptor expression in endometrial cancer. Int J Gynecol Pathol 2009; 28: 19-22
  7. Manni A, Santen R, Harvey H, Lipton A, Max D. Treatment of breast cancer with gonadotropin-releasing hormone. Endocr Rev 1986; 7: 89-94
  8. Iversen P, Suciu S, Sylvester R, Christensen I, Denis L. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. Cancer 1990; 66: 1067-73
  9. Gallagher CJ, Oliver RT, Oram DH, Fowler CG, Blake PR, Mantell BS, et al. A new treatment for endometrial cancer with gonadotropin releasing hormone analogue. Br J Obstet Gynaecol 1991; 98: 1037-41
  10. Emons G, Ortmann O, Pahwa GS, Hackenberg R, Oberheuser F, Schultz KD. Intracellular action of gonadotropic and peptide hormones and the therapeutic value of GnRH agonist in ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992; 155: 31-8
  11. Huirne JA, Lambalk CB. Gonadotropin-releasing hormone receptor antagonist. New drug classes. Lancet 2001; 358: 1793-803
  12. Kleinman D, Douvdevani A, Schally AV, Levy J, Sharoni Y. Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis. Am J Obstet Gynecol 1994; 170: 96-102
  13. Emons G, Muller V, Ortmann O, Schultz KD. Effect of LHRH analogues on mitogenic signal transduction in cancer cells. Steroid Biochem Mol Biol 1998; 65: 1